Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients

Background and Aims: The majority of patients treated with anti-tumor necrosis factor (TNF) therapy develop anti-drug antibodies (ADAs), which might result in loss of treatment efficacy. Strict guidelines on measuring trough levels (TLs) and ADA in clinical routine do not exist. To provide real-worl...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Inflammatory intestinal diseases 2021-02, Vol.6 (1), p.38-47
Hauptverfasser:	Reinhold, Ilana, Blümel, Sena, Schreiner, Jens, Boyman, Onur, Bögeholz, Jan, Cheetham, Marcus, Rogler, Gerhard, Biedermann, Luc, Scharl, Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	adalimumab anti-drug antibodies anti-tumor necrosis factor crohn’s disease inflammatory bowel disease infliximab Research Article trough level measurement ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!